Bacteriocins produced by a variety of microbes are gaining more attention for not only as alternative foodpreservative but also as therapeutics agent. A bacteriocin, Ent C4L10, was produced by coagulase negative Enterococcus mundtii strain C4L10 (Accession No. KC731423) previously isolated from Malaysian non-broiler chicken. Based on agar diffusion assay, it showed antimicrobial activities against Methicillin resistance Staphylococcus aureus (MRSA) used as an indicator organism. Approximately 10 kDa protein was purified employing three-phase partitioning (TPP) method and it was shown to be highly thermostable, retaining activities at 121°C for 15 min, and was stable in a pH range of 4-9. There was however a loss in activity after protease treatment. PCR amplification using enterocin gene primers showed that Ent C4L10 sequence is highly similar to bacteriocinL-1077 (83% identity). In order to study its anti-proliferative potential, purified Ent C4L10 was also tested against four human cell lines; i.e., lung cancer (H1299), breast cancer (MCF 7), colon cancer (HCT116) and oral cancer (HSC3). It was found that oral cancer cell line wasthe most sensitive with a cytotoxic index of IC50 of 9.009 µg/ml, followed by breast cancer IC50 (11.51 µg/ml), and the least sensitive was with colon cancer cell line (IC50 of 20.57 µg/ml). In conclusion, putative 10KDaEnt C4L10 is a class II bacteriocin isolated from coagulase negative Enterococcus mundtii strain C4L10 shown to have anti-proliferative properties. Therefore, this bacteriocin has not only great potential for use in food preservation, its future use as an antitumoragent should also be explored.

Speaker Presentations

Speaker PDFs

Speaker PPTs

Download PPT